| Title: |
Weight gain following antiretroviral therapy (ART) initiation in ART-naïve people living with HIV in the current treatment era |
| Authors: |
Ruderman, SA; Crane, HM; Nance, RM; Whitney, BM; Harding, BN; Mayer, KH; Moore, RD; Eron, JJ; Geng, E; Mathews, WC; Willig, AL; Burkholder, GA; Lindström, S; Wood, BR; Collier, AC; Vannappagari, V; Henegar, C; Van Wyk, J; Curtis, L; Saag, MS; Kitahata, MM; Delaney, JAC |
| Source: |
J Acquir Immune Defic Syndr |
| Publication Year: |
2021 |
| Subject Terms: |
Article; archeo; anthro-se |
| Description: |
OBJECTIVES: Evaluate differences in weight change by regimen among people living with HIV (PLWH) initiating antiretroviral therapy (ART) in the current era. METHODS: Between 2012–2019, 3232 ART-naïve PLWH initiated ≥3-drug ART regimens in eight Centers for AIDS Research Network of Integrated Clinical Systems (CNICS) sites. We estimated weight change by regimen for 11 regimens in the immediate (first 6-months) and extended (all follow-up on initial regimen) periods using linear mixed models adjusted for time on regimen, interaction between time and regimen, age, sex, race/ethnicity, hepatitis B/C coinfection, nadir CD4, smoking, diabetes, antipsychotic medication, and site. We included more recently approved regimens (e.g. with tenofovir alafenamide fumarate (TAF)) only in the immediate period analyses to ensure comparable follow-up time. RESULTS: Mean follow-up was 1.9 years on initial ART regimen. In comparison to efavirenz/tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC), initiating bictegravir/TAF/FTC (3.9kg (95%CI:2.2–5.5)) and dolutegravir/TAF/FTC (4.4kg (95%CI:2.1–6.6)) were associated with the greatest weight gain in the immediate period, followed by darunavir/TDF/FTC (3.7kg (95%CI:2.1–5.2)) and dolutegravir/TDF/FTC (2.6kg (95%CI:1.3–3.9). In the extended period, compared with efavirenz/TDF/FTC, initiating darunavir/TDF/FTC was associated with a 1.0kg (95%CI:0.5–1.5) per 6-months greater weight gain, while dolutegravir/abacavir/FTC was associated with a 0.6kg (95%CI:0.3–0.9) and dolutegravir/TDF/FTC was associated with a 0.6kg (95%CI:0.1–1.1) per 6-months greater gain. Weight gain on dolutegravir/abacavir/FTC and darunavir/TDF/FTC was significantly greater than that for several integrase inhibitor-based regimens. CONCLUSIONS: There is heterogeneity between regimens in weight gain following ART initiation among previously ART-naïve PLWH; we observed greater gain among PLWH taking newer INSTIs (DTG, BIC) and DRV-based regimens. |
| Document Type: |
text |
| Language: |
English |
| Relation: |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878311/ |
| Availability: |
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7878311/ |
| Rights: |
undefined |
| Accession Number: |
edsbas.8D7737D4 |
| Database: |
BASE |